**Background**
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. A key player in the regulation of glucose homeostasis is dipeptidyl peptidase IV (DPP-4), an enzyme that rapidly degrades incretin hormones, such as glucagon-like peptide-1 (GLP-1). These incretins are essential for stimulating insulin secretion from pancreatic beta cells in a glucose-dependent manner and suppressing glucagon release. By inhibiting DPP-4, the levels of active GLP-1 are maintained, thereby enhancing insulin secretion and lowering blood glucose levels. Consequently, DPP-4 inhibitors have become a significant focus for the development of therapeutic agents to manage type 2 diabetes. In this context, we will introduce a potent and orally active DPP-4 inhibitor – K579.
**Definition**
K579 is a potent dipeptidyl peptidase IV (DPP-4) inhibitor with the molecular formula C17H24N6O. According to the K579 description, it is an orally active compound designed to inhibit blood glucose elevation.
**In Vitro and In Vivo Studies**
The K579 biological activity is characterized by its ability to act as a slow-binding inhibitor of DPP-4, which contributes to its efficacy as a long-acting hypoglycemic agent. In terms of K579 in vivo performance, administration of the compound has been shown to effectively inhibit the elevation of blood glucose. Furthermore, K579 increases the plasma concentrations of insulin as well as the active forms of glucagon-like peptide-1 (GLP-1), which are critical for the regulation of glucose metabolism. These pharmacological properties suggest that K579 has significant potential for the research of diabetic conditions. In conclusion, K579 is a potent, orally active, and long-acting DPP-4 inhibitor that holds promise for the study and treatment of diabetes.
Keywords
K579, 440100-64-1, K 579, K-579, Dipeptidyl Peptidase, DPP, orally active, blood glucose, insulin, GLP-1, antidiabetic, Inhibitor, inhibitor, inhibit
References